Adhera Therapeutics Selects IQVIA’s OCE Technology Platform to Support Commercial Excellence
November 20 2018 - 8:00AM
Business Wire
Innovative Technology enables the
pharmaceutical industry to transition to an orchestrated commercial
model
IQVIA™ (NYSE:IQV) today announced that Adhera Therapeutics Inc.
(OTCQB:ATRX) has selected Orchestrated Customer Engagement (OCE),
IQVIA Technologies’ transformational commercial platform, to build
its commercial infrastructure and bring the company’s specialty
drug innovations to patients.
OCE accelerates a transformation in commercial engagement for
life sciences companies by connecting functions, data, insights,
and activities horizontally to break down silos and provide a
holistic view of the customer. This gives the company and its
clients, a streamlined, more valuable customer experience. Adhera
Therapeutics will leverage the OCE technology platform to deliver
more intelligent and actionable insight to its commercial
teams.
“We have confidence that IQVIA’s OCE platform will support our
mission to develop and commercialize unique pharmaceutical
therapies and leverage technology to improve patient outcomes,”
said Robert C. Moscato, Jr., chief executive officer of Adhera
Therapeutics. “We wanted to provide our sales team and home office
users with the leading technology to support our current business
needs but also have a customer relationship management solution
that will support our future needs as we grow.”
Pharmaceutical companies are making IQVIA’s OCE the new
commercial standard because it is easy to use, enables connectivity
across all commercial functions, and surfaces actionable insights
into marketing and sales teams’ workflow. The platform will allow
Adhera to start from scratch as it builds and strengthens a true
commercial infrastructure over time.
“We are pleased that Adhera will be implementing our OCE
technology platform,” said Tal Rosenberg, senior vice president,
Global Technology Solutions at IQVIA. “IQVIA has a proven portfolio
of innovative technology solutions including CRM specifically
designed for life sciences. Adhera understands that the value of
our new OCE platform is its ability to capitalize on this deep
industry knowledge. In short, OCE helps companies improve their
customer engagement model by creating a better user experience,
connecting all commercial team members, and efficiently delivering
tailored insight to each unique commercial team member.”
About Adhera Therapeutics
Adhera Therapeutics, Inc. is a specialty pharmaceutical company
leveraging technology to commercialize unique therapies and improve
patient outcomes. The company is initially focused on
commercializing PRESTALIA® (perindopril arginine and amlodipine
besylate) through DyrctAxess, a patient-centric treatment approach.
Our PRESTALIA product is approved by the US FDA for the treatment
of hypertension to lower blood pressure. Adhera is dedicated to
identifying additional assets to expand our commercial presence.
Additional information can be found at
www.adheratherapeutics.com.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions and contract research services to
the life sciences industry. Formed through the merger of IMS Health
and Quintiles, IQVIA applies human data science — leveraging the
analytic rigor and clarity of data science to the ever-expanding
scope of human science — to enable companies to reimagine and
develop new approaches to clinical development and
commercialization, speed innovation and accelerate improvements in
healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers
unique and actionable insights at the intersection of large-scale
analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With more than 55,000
employees, IQVIA conducts operations in more than 100
countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing the information that helps its customers
drive human health outcomes forward. IQVIA’s insights and execution
capabilities help biotech, medical device and pharmaceutical
companies, medical researchers, government agencies, payers, and
other healthcare stakeholders tap into a deeper understanding of
diseases, human behaviors, and scientific advances, in an effort to
advance their path toward cures. To learn more, visit
www.iqvia.com.
Click here to subscribe to Mobile Alerts for IQVIA.
IQVIAFIN
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181120005323/en/
Tor ConstantinoIQVIA Media
Relationstor.constantino@iqvia.com+1.484.567.6732orAndrew
MarkwickIQVIA Investor
Relationsandrew.markwick@iqvia.com+1.973.257.7144
IQVIA (NYSE:IQV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Jul 2023 to Jul 2024